Effect of different anti-rejection regimens on the expression of differentiation and activation markers on the surface of host lymphocytes.
Malinowski
K
K
Department of Urology and Transplantation Service, State University of New York at Stony Brook, Stony Brook, New York 11794-8192, USA.
Ye
H
H
Waltzer
W C
WC
D015703:Antigens, CD / Q000097:blood*; D001379:Azathioprine / Q000627:therapeutic use; D002454:Cell Differentiation; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology*; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
D015703:Antigens, CD; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine; D016559:Tacrolimus